NPPB and hydrops fetalis: Notably, in 2019, a baroreceptor activation treatment (BAT) device gained FDA approval in patients with advanced HF, based on the BeaT-HF trial [118], which showed significant improvements in quality of life, exercise capacity, and levels of NT-proBNP, while a recent, independent patient data meta-analysis also supports the safety and efficacy of this device in patients with HFrEF [119].